Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sam Schulman

Showing results (31-40 of 308) with videos related to

Pageof 31
Sort By:
Seminars in Thrombosis and Hemostasis|May 12, 2020
Coronavirus Disease 2019, Prothrombotic Factors, and Venous ThromboembolismSam Schulman
Blood|May 10, 2017
How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapySam Schulman
Nature Clinical Practice. Cardiovascular Medicine|June 21, 2007
Is 3 months the optimum duration of anticoagulation therapy for deep vein thrombosis and pulmonary embolism?Sam Schulman
Current Opinion in Pulmonary Medicine|May 24, 2012
Treatment of venous thromboembolism with dabigatranSam Schulman
The Lancet. Haematology|September 12, 2018
Splanchnic vein thrombosis: what are the long-term risks?Sam Schulman
Seminars in Thrombosis and Hemostasis|October 21, 2016
Update on the Treatment of Venous ThromboembolismSam Schulman
Lakartidningen|June 11, 2004
[Low molecular weight heparin--a safer anticoagulant in thrombosis and cancer]Sam Schulman
Thrombosis and Haemostasis|September 2, 2017
Accumulating data on rivaroxaban for venous thromboembolism in clinical practiceSam Schulman
Lakartidningen|June 20, 2008
[Bleeding time--only in special cases. The method is of little value as a general screening analysis]Sam Schulman
Seminars in Thrombosis and Hemostasis|February 7, 2013
Optimal duration of anticoagulant therapySam Schulman
Pageof 31

Showing results (31-40 of 308) with videos related to

Sort By:
Pageof 31
Seminars in Thrombosis and Hemostasis|May 12, 2020
Coronavirus Disease 2019, Prothrombotic Factors, and Venous ThromboembolismSam Schulman
Blood|May 10, 2017
How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapySam Schulman
Nature Clinical Practice. Cardiovascular Medicine|June 21, 2007
Is 3 months the optimum duration of anticoagulation therapy for deep vein thrombosis and pulmonary embolism?Sam Schulman
Current Opinion in Pulmonary Medicine|May 24, 2012
Treatment of venous thromboembolism with dabigatranSam Schulman
The Lancet. Haematology|September 12, 2018
Splanchnic vein thrombosis: what are the long-term risks?Sam Schulman
Seminars in Thrombosis and Hemostasis|October 21, 2016
Update on the Treatment of Venous ThromboembolismSam Schulman
Lakartidningen|June 11, 2004
[Low molecular weight heparin--a safer anticoagulant in thrombosis and cancer]Sam Schulman
Thrombosis and Haemostasis|September 2, 2017
Accumulating data on rivaroxaban for venous thromboembolism in clinical practiceSam Schulman
Lakartidningen|June 20, 2008
[Bleeding time--only in special cases. The method is of little value as a general screening analysis]Sam Schulman
Seminars in Thrombosis and Hemostasis|February 7, 2013
Optimal duration of anticoagulant therapySam Schulman
Pageof 31